Hua MedicineHUMDF 46 OCF Yield % is -2.86 as of Jun. 29, 2026. GuruFocus rates HUMDF with a GF Score™ of 46/100 and a GF Value™ of $1.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,002 Drug Manufacturers companies, Hua Medicine ranks worse than 76.85% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Hua Medicine OCF Yield % Related Terms
Hua Medicine OCF Yield % Historical Data
* Premium members only.
The historical data trend for Hua Medicine's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hua Medicine OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Hua Medicine's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hua Medicine (HUMDF) has a OCF Yield % of -2.86 as of Jun. 29, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Hua Medicine and its competitors. According to the industry distribution chart, Hua Medicine ranks #770 out of 1002 companies in the Drug Manufacturers industry, placing it in the top 76.8%.
Is Hua Medicine's OCF Yield % too high?
Hua Medicine's current OCF Yield % is -2.86. Based on the distribution chart, Hua Medicine ranks #770 out of 1002 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hua Medicine has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hua Medicine's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hua Medicine ranks #770 out of 1002 companies for OCF Yield %. This places Hua Medicine in the lower half of its industry. The industry median OCF Yield % is 3.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.61, based on 1,002 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Hua Medicine and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hua Medicine's current OCF Yield % is -2.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hua Medicine stock overvalued right now?
Based on GuruFocus' analysis, Hua Medicine (HUMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.46, compared to a current price of $0.34 — trading 76.7% below its estimated fair value. The current OCF Yield % is -2.86. Hua Medicine's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Hua Medicine (HUMDF), the current OCF Yield % is -2.86 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hua Medicine (HUMDF) Overvalued in 2026?
Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued.
The current stock price of $0.34 is trading 76.7% below its estimated GF Value™ of $1.46.
GuruFocus considers Hua Medicine to be Possible Value Trap.
Key valuation signals for HUMDF:
OCF Yield %: -2.86
GF Value™: $1.46 vs. price of $0.34 (76.7% below fair value)
No single metric tells the full story. See the HUMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
46GF Score
Get the complete analysis for HUMDF
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HUMDF has been successfully added to your 
